Purpose Thioredoxin-1 (Trx-1) redox signaling regulates multiple aspects of cell growth and survival, and elevated tumor levels of Trx-1 have been associated with decreased patient survival. PX-12, an inhibitor of Trx-1 currently in clinical development, has been found to decrease tumor levels of the HIF-1 transcription factor. SSAT1 has been reported to bind to HIF-1 and RACK1, resulting in oxygen-independent HIF-1 ubiquitination and degradation. SSAT2, a related protein, stabilizes the interaction of the VHL protein and elongin C with HIF-1 leading to oxygen-dependent HIF-1 ubiquitination and degradation. We investigated the eVects of PX-12 and Trx-1 on SSAT1, SSAT2, and inhibition of HIF-1 . Methods A panel of cell lines was treated with PX-12 to investigate its eVects on SSAT1 and SSAT2 expression, and on HIF-1 protein levels. We also evaluated the regulation of SSAT1 through the Nrf2 and PMF-1, two trans-acting transcription factors. Results We found that PX-12 increased nuclear Nrf2 activity and antioxidant response element binding. PX-12 also increased the expression of SSAT1 but not SSAT2 in a PMF-1-dependent manner that was independent of Trx-1. Inhibition of Nrf2 or PMF-1 prevented the increase in SSAT1 caused by PX-12.
Introduction
Thioredoxin-1 (Trx-1) is a small (12 kDa) redox protein that is an important regulator of many aspects of cell proliferation and survival [1] . Thioredoxin reductase, a homodimeric Xavoprotein, transfers reducing equivalents from NADPH to Trx-1, which then acts as a redox cofactor and a cellular antioxidant through the transfer of reducing equivalents to peroxiredoxins [2] . Trx-1 also increases the DNA binding of redox-sensitive transcription factors such as activator protein-1 (AP-1) and nuclear factor kappa-B (NF-B) [3] , and binds to and inhibits proapoptotic proteins including apoptosis signal-regulating kinase-1 (Ask-1) [4] and the tumor suppressor PTEN (phosphatase and tensin homolog) [5] , which attenuates the activity of the phosphatidylinositol-3-kinase/Akt cell survival pathway in cancer cells. Trx-1 is overexpressed in many human cancers including lung, colon, cervix, stomach, and pancreatic cancer [1] , where it is associated with aggressive tumor growth, decreased patient survival [6, 7] , and resistance to chemotherapy [8, 9] . We have previously reported that Trx-1 increases the levels of the hypoxia-inducible transcription factor-1alpha (HIF-1 ) under both normoxic and hypoxic conditions and increases the expression of HIF-1 downstream targets such as vascular endothelial growth factor (VEGF) leading to increased tumor angiogenesis [10] . We have also suggested that Trx-1 may play a role in the redox regulation of spermidine/spermine N(1)-acetyl transferase 1 (SSAT1) and polyamine homeostasis, which could contribute to the biological eVects of Trx-1 [11] . SSAT1 is a polyamine catabolic enzyme that acetylates spermidine and spermine, thus reducing their potency. SSAT1 acts in concert with spermine oxidase and N(1)-acetylpolyamine oxidase to regulate polyamine metabolism [12] . SSAT1 is transcriptionally regulated through the interaction of two trans-acting transcription factors, nuclear factor erythroidderived 2 (NF-E2)-related factor 2 (Nrf2) and polyamine modulated factor-1 (PMF-1) [13] . SSAT1 binding has been reported to stabilize the interaction between hypoxiainduced HIF-1 , RACK-1 (receptor for activated C kinase-1), and elongin C, thus promoting oxygen-independent HIF-1 ubiquitination and degradation [14] . SSAT2 has 64% similarity and 46% homology to SSAT1 [15] but has a much lower level of acetyltransferase activity toward polyamines and a lower level of expression than SSAT1 [16] [17] [18] . SSAT2 has been reported to stabilize the interaction of the von Hippel-Lindau protein (pVHL) and elongin C with HIF-1 and lead to oxygen-dependent HIF-1 ubiquitination and degradation [19] .
PX-12, 1-methylpropyl 2-imidazolyl disulWde, is a Trx-1 inhibitor that shows antitumor activity in both in vitro and in vivo [20] and that is currently in clinical development [21] . We have previously reported that PX-12 lowers tumor HIF-1 protein levels and inhibits HIF-1 transactivating activity and the expression of the downstream targets of HIF-1 , including VEGF [21] [22] [23] [24] . In the present study, we investigated the regulation of HIF-1 by PX-12 and the associated roles of Trx-1, SSAT1, and SSAT2. We found that PX-12 increases SSAT1 expression and decreases HIF-1 levels independently of Trx-1 and that SSAT2 does not play a role in HIF-1 degradation by PX-12.
Materials and methods

Cells and reagents
Human MiaPaCa-2 pancreatic cancer cells, MCF-7 breast cancer cells, LN-229 glioma cancer cells, and HEK-293 transformed embryonic kidney cells were obtained from American Type Culture Collection (Manassas, VA). Monoclonal antibodies to human HIF-1 , RACK1, and elongin C were purchased from BD Transduction Laboratories (San Diego, CA), and antibodies to Trx-1, Trx-2, Trx-reductase-1 and -2, lamin A/C, -actin, NAD(P)H dehydrogenase, quinone 1 (NQO1), and Nrf2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). PX-12 was synthesized [20] , and MG-132 was purchased from SigmaAldrich (St. Louis, MO).
Cell culture
MiaPaCa-2, HEK-293, and LN-229 cells were cultured in Dulbecco's minimum essential medium (Cellgro, Mediatech, Manassas, VA) and 10% fetal calf serum (Hyclone Laboratories, Logan, UT) at 37°C in 5% CO 2 . MCF-7 cells were cultured in minimum essential medium (Cellgro) and 10% fetal calf serum. All cell lines were genetically veriWed by the M. D. Anderson Cell Line Characterization Service. For assay, cells were incubated for various times at 37°C in humidiWed air, 5% CO 2 (normoxia), or 1% O 2 , 5% CO 2 , 94% N 2 (hypoxia) using an Invivo Hypoxia Workstation 400 with Ruskinn hypoxic gas mixer (Ruskinn Technology, Pencoed, UK). Cells (2.5 £ 10 5) ) were seeded and grown under normoxic conditions to 70% conXuence and then incubated under hypoxic conditions for 16-24 h in the presence or absence of PX-12. Cells cultured under hypoxic conditions were collected under hypoxic conditions.
Western blotting
Cells were grown under normoxic or hypoxic conditions in the presence or absence of 25 M PX-12. The cells were washed twice in phosphate-buVered saline, and Western blotting was performed as previously described [11] . Blots were quantiWed using ImageQuant software (Molecular Dynamics/GE Healthcare Biosciences, Pittsburgh, PA).
Nuclear and cytoplasmic extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce/Thermo Fisher ScientiWc, Rockford, IL) in accordance with the manufacturer's protocols.
Real-time reverse transcription-PCR analysis
Total RNA was isolated from cell lysates using the PARIS kit (Ambion/Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. TaqMan quantitative reverse transcription (RT)-PCR was performed on the ABI 7300 system using the TaqMan one-step reverse transcription-PCR Master Mix kit and predesigned primer/probe pairs for SSAT1, SSAT2, Nrf2, PMF-1, and 2 -microglobulin (Applied Biosystems, Foster City, CA). Normalization and analyses were carried out with 2 -microglobulin (B 2 M) using the 2(-delta-delta C(T)) method as the internal reference [25] and with Applied Biosystems GeneAmp 5700 SDS software. All measurements were performed in triplicate.
Small interfering RNA transfection
Small interfering RNA (siRNA) SMARTpool sequences were obtained from Dharmacon/Thermo Fisher ScientiWc (Waltham, MA), and the cells were transfected with 25 nM siRNA-Trx-1, siRNA-EIF2AK3 (PERK), siRNA-Nrf-2, siRNA-SSAT1, siRNA-SSAT2, siRNA-PMF-1, siRNA-HIF-1 , or a siRNA nontargeting control using Dharma-FECT-1 lipid transfection reagent. The transfection medium was removed after 24 h and replaced with fresh medium, and the cells were grown in 5% CO 2 at 37°C for an additional 48-72 h. Western blot analyses were performed to conWrm target knockdown by siRNA. Transfected cells were treated with PX-12 and cultured under normoxic or hypoxic conditions for an additional 16-18 h.
DNA-binding assay
Nuclear extracts were obtained using the Nuclear Extract Kit (Active Motif, Carlsbad, CA) in accordance with the 
Statistical analysis
SigniWcance was determined using student's t test to compare data points with control data. Results at p < 0.05 were considered signiWcant.
Results
PX-12 decreases hypoxia-induced HIF-1 levels and increases SSAT1
PX-12 decreased hypoxia-induced HIF-1 protein levels in a panel of four cell lines (MiaPaCa-2, MCF-7, HEK-293, and LN-299) conWrming earlier observations [22] (Fig. 1a) .
The proteosomal inhibitor MG-132 was used to determine whether the PX-12-mediated decrease in HIF-1 was the result of increased proteosomal degradation (Fig. 1b) . The results show that PX-12 was still able to decrease HIF-1 protein level in the presence of MG-132. PX-12 also increased the expression of SSAT1 under both normoxic and hypoxic conditions in all 4 cell lines (Fig. 1c) . SSAT2 expression was not increased by PX-12 under either normoxic or hypoxic conditions.
Trx-1 is not required for PX-12 to decrease HIF-1 levels and/or SSAT1 expression
Trx-1 knockdown with siRNA did not decrease hypoxiainduced HIF-1 protein levels although Trx-1 protein levels were markedly decreased (Fig. 2a) . We previously reported that transfection of cells with dominant-negative redoxinactive Trx-1 inhibited hypoxia-induced HIF-1 protein levels [10] . The diVerence with the present results using siRNA-Trx-1 may be due to oV target eVects of the redoxinactive Trx-1. Furthermore, siRNA knockdown of Trx-1 did not inhibit the increase in SSAT1 caused by PX-12 in either normoxia or hypoxia (Fig. 2b) . It should be noted that for unknown reasons, knockdown of Trx-1 actually increased SSAT1 expression. There was no signiWcant eVect of Trx-1 knockdown on SSAT2 expression.
PX-12 increases nuclear Nrf2 expression and binding to the ARE PX-12 was found to increase nuclear Nrf2 protein levels in MiaPaCa-2 cells, but not to aVect the levels of Nrf2 protein in the cytoplasm (Fig. 3a) . At the same time, Nrf2 binding to the ARE was increased by PX-12 at 10 and 25 M; however, at 50 M, PX-12 inhibited ARE binding possibly due to a decrease in nuclear Nrf2 at this high concentration of PX-12 (Fig. 3b) . The endoplasmic reticulum stress response acting through PERK can activate Nrf2 [26] . However, PX-12, 25 M, was able to increase Nrf2 expression under hypoxic conditions even when PERK was inhibited (Fig. 3c) . PX-12 signiWcantly increased the binding of Nrf2 to the ARE in the panel of 4 cell lines (Fig. 3d ) but failed to increase the binding in siRNA-Nrf2-treated cells, while siRNA-PMF1, siRNA-SSAT1, and siRNA-Trx-1 had no eVect on ARE binding (Fig. 3e) . PX-12 increased total levels of SSAT1 in hypoxic MiaPaCa-2 and MCF-7 cells but only increased Nrf2 under hypoxic conditions and when Trx-1 was knocked down with siRNA-Trx-1 (Fig. 4a, b) .
PX-12 and downstream targets of the ARE
Although PX-12 increased hypoxia-induced Nrf2 levels in the absence of Trx-1, and increased Nrf2 binding to the ARE in hypoxic MiaPaca-2 cells, it had no eVect on the levels of typical ARE downstream targets suggesting that ARE-bound Nrf2 is nonfunctional possibly (Fig. 4c ). This could be as a result of modiWcation of Nrf2 by PX-12. However, in hypoxic MCF-7 breast cancer cells, PX-12 caused a decrease in ARE downstream targets, including thioredoxin reductase 1, RACK1, and elongin C (Fig. 4d) . As expected, PX-12 decreased HIF-1 and Trx-1 levels in both the MiaPaCa-2 and MCF-7 cell lines. The results suggest a complex eVect on antioxidant activity that is not mediated by the ARE or SSAT1 and which is perhaps dependent on the intrinsic oxidant stress state of the cells. Hypoxia is known to increase the production of reactive oxygen species through a process mediated by the mitochondria [25] , which could vary between cell lines. Both Nrf2 and PMF-1 appear to be necessary for hypoxia-induced SSAT1 mRNA expression, and PX-12 does not induce SSAT1 mRNA expression when either Nrf2 or PMF-1 is knocked down (Fig. 5a ). SSAT2 mRNA expression was not aVected by a loss of Nrf2 or PMF-1 (Fig. 5b) . Trx-1 siRNA treatment of MiaPaCa-2 cells showed an increase in PMF-1 in hypoxic conditions, with and without the addition of PX-12 (Fig. 5c) . 
Discussion
In a previous study, we suggested that Trx-1 might regulate polyamine levels in breast cancer cells through a decrease in SSAT1 expression and this might contribute to the growth-stimulating and antiapoptotic eVects of Trx-1 [11] . SSAT1 expression is transcriptionally regulated through the interaction of two trans-acting transcription factors, Nrf2 and PMF-1 [13] . SSAT1 functions in polyamine catabolism and contributes to the regulation of intracellular pools of the polyamines putresceine, spermidine, and spermine. The closely related SSAT2 cannot acetylate polyamines and its likely physiological substrate is thialysine, which is formed by the reaction of L-serine and cysteamine catalyzed by cystathionine--synthase [17] . SSAT1 and SSAT2 both promote HIF-1 degradation but by diVerent mechanisms. SSAT1 stabilizes the binding of RACK1 and elongin C with HIF-1 , thus promoting the oxygenindependent ubiquitination and degradation of HIF-1 [14] ; SSAT2 stabilizes the binding of pVHL and elongin C with HIF-1 and because pVHL requires oxygen-dependent proline hydroxylation of HIF-1 , this leads to oxygendependent HIF-1 ubiquitination and degradation [19] . We anticipated that PX-12 would counteract the eVects of 
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Trx-1, resulting in an increase in SSAT1, and thus a decrease in HIF-1 levels. We were therefore surprised to Wnd that PX-12 increased SSAT1 expression and decreased HIF-1 levels independently of Trx-1. We were also interested to see if there might be an increase in SSAT2 Wnding that its expression level was not increased by PX-12 and that SSAT2 did not play a role in HIF-1 degradation by PX-12.
Nrf2 activates ARE-mediated gene expression and mediates the primary antioxidant response to an oxidative challenge in cells [27, 28] . Interaction of the leucine zipper region of Nrf2 with the c-terminal coiled-coil region of PMF-1 increases the expression of SSAT1 and its response to polyamines [13, 29] . Nrf2 is kept in the cytoplasm in a complex with Kelch-like ECH-associated protein 1 (Keap1), from which it is released by the oxidization of critical cysteine residues. This leads to the nuclear translocation and accumulation of Nrf2 [30] . We found increased levels of nuclear Nrf2 and Nrf2 binding to the ARE in cells treated with PX-12. Nrf2 is also activated by PERK-dependent phosphorylation that leads to dissociation of the Nrf2/ Keap1 complex [26] ; however, we found that PX-12 increased Nrf2 independently of PERK. We found that PX-12 indirectly increases Nrf2 through its inhibitory eVect on Trx-1, but also directly increases Nrf2 expression under hypoxic conditions by a process that is independent of Trx-1. The latter mechanism appears to be the primary means by which PX-12 increases Nrf2. It is noteworthy that the PX-12-induced Nrf2 increase we found in one of the cell lines was not accompanied by increased expression of ARE downstream targets. This suggests a possible cell contextdependent eVect for the antioxidant response.
The Sat1 gene encoding SSAT1 contains a positive regulatory element (PRE)-binding site. Along with increases in the levels of Nrf2 and SSAT1 mRNA caused by PX-12, we also found evidence of increased PRE binding suggesting that a Nrf2/PMF-1 mechanism is responsible for the increase in SSAT1 by PX-12. Inhibiting either Nrf2 or PMF-1 prevented the increase in SSAT1 by PX-12. Baek et al. [14] have shown that SSAT1 plays an essential role in the RACK1-mediated ubiquitination of HIF-1 and suggested that this leads to 26S proteasome-dependent HIF-1 degradation. However, we found that the decrease in HIF-1 by PX-12 was insensitive to proteasome inhibition with MG-132, which suggests that another degradation mechanism may be involved.
Thus, the eVect of PX-12 in decreasing HIF-1 may occur through multiple mechanisms (Fig. 6) . The results of our study show that PX-12 decreases HIF-1 protein levels by an oxygen-independent pathway through an increase in SSAT1 expression mediated by Nrf2 activation and increased ARE binding. Furthermore, we found that this activity of PX-12 is independent of its ability to inhibit Trx-1. Although SSAT2 is essential to the stabilization of pVHL in the oxygen-dependent degradation pathway, PX-12 did not aVect SSAT2 expression levels. In conclusion, we have shown that PX-12 is an inhibitor of HIF-1 through Nrf2/PMF-1 complex formation and the induction of SSAT1.
